Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;14(4):399–405. doi: 10.1111/j.1750-3639.2004.tb00083.x

Galectin‐3 as an Immunohistochemical Tool to Distinguish Pilocytic Astrocytomas from Diffuse Astrocytomas, and Glioblastomas from Anaplastic Oligodendrogliomas

Luciano Neder 1, Suely K Nagahashi Marie 2,✉, Carlos Gilberto Carlotti Jr 3, Alberto Alain Gabbai 4, Sérgio Rosemberg 5, Suzana MF Malheiros 4, Rodrigo Proto Siqueira 6, Sueli Mieko Oba‐Shinjo 2, Miyuki Uno 2, Paulo Henrique Aguiar 2, Flavio Miura 2, Roger Chammas 7, Benedicto Oscar Colli 3, Wilson Araujo Silva Jr 8, Marco A Zago 6
PMCID: PMC8096060  PMID: 15605987

Abstract

The distinction of astrocytomas and oligodendrogliomas, mainly pilocytic astrocytomas (PILOs) from infiltrating astrocytomas and oligodendrogliomas (ODs), and high‐grade oligodendrogliomas from glioblastomas (GBMs), poses a serious clinical problem. There is no useful immunohistochemical (IHC) marker to differentiate these gliomas, and sometimes the differential diagnosis between them is arbitrary. We identified galectin‐3 (Gal‐3) as a possible tool to differentiate them based on gene expression profiles of GBMs. We confirmed the differential expression in 45 surgical samples (thirteen GBMs; seven PILOs; 5 grade II ODs; 5 anaplastic oligodendrogliomas [AODs], including 2 Oligo‐astrocytomas; 8 diffuse astrocytomas [ASTs], and 7 non‐neoplastic samples) by quantification of Gal‐3 gene expression by real‐time quantitative PCR (rt‐PCR). Higher expression of Gal‐3 was observed in GBMs and PILOs than in OD, AODs and ASTs. The IHC expression of Gal‐3 was evaluated in 90 specimens (fifteen PILOs, fourteen ASTs, 10 anaplastic astrocytomas, fifteen GBMs, eleven ODs, fifteen AODs, and 10 dysembryoplastic neuroepithelial tumors). The mean labeling score for Gal‐3 determined according to the percentage of labeled cells in the tumor bulk was significantly different in GBMs versus AODs and in PILOs versus ASTs. Hence, Gal‐3 is differentially expressed in central nervous system tumors, making IHC detection of Gal‐3 a useful tool in distinguishing between these gliomas.

Full Text

The Full Text of this article is available as a PDF (515.1 KB).

REFERENCES

  • 1. Almkvist J, Karlsson A (2004) Galectins as inflammatory mediators. Glycoconj J 19:575–581. [DOI] [PubMed] [Google Scholar]
  • 2. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Lui F, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PW, Rini JM, Wang JL (1994b) Galectins: a family of animal β‐galactoside‐binding lectins. Cell 76:597–598. [DOI] [PubMed] [Google Scholar]
  • 3. Brat DJ, Castellano‐Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B, Meir EGV (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920–927. [DOI] [PubMed] [Google Scholar]
  • 4. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A (1997) Expression of the endogenous galactosebinding protein galectin‐3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80:776–787. [PubMed] [Google Scholar]
  • 5. Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotqui J, Zick Y, Salmon I, Gabius HJ, Kiss R (2001) Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and modulate tumor astrocyte migration. Brain Pathol 11:12–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Cooper DNW, Barondes SH (1999) God must love galectins; he made so many of them. Glycobiology 9:919–984. [DOI] [PubMed] [Google Scholar]
  • 7. Cowles EA, Agrwal N, Anderson RL, Wang JL (1990) Carbohydrate‐binding protein 35.Isoelectric points of the polypeptide and a phosphorylated derivative. J Biol Chem 265:17706–17712. [PubMed] [Google Scholar]
  • 8. Danguy A, Camby I, Kiss R (2002) Galectins and cancer. Biochem Biophys Acta 1572:285–293. [DOI] [PubMed] [Google Scholar]
  • 9. Daumas‐Duport C, Beuvon F, Varlet P, Fallet‐Bianco C (2000) Gliomas: WHO and Sainte‐Anne Hospital classifications. Ann Pathol 20:413–428. [PubMed] [Google Scholar]
  • 10. Deininger MH, Trautmann K, Meyermann R, Schluesener HJ (2002) Galectin‐3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. Anticancer Res 22:1585–1592. [PubMed] [Google Scholar]
  • 11. Engelhard HH, Stelea A, Cochran EJ (2002) Oligodendroglioma: pathology and molecular biology. Surg Neurol 58:111–117. [DOI] [PubMed] [Google Scholar]
  • 12. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, Kagawa S, Raz A (2003) CD29 and CD7 mediate galectin‐3‐induced type II T‐cell apoptosis. Cancer Res 63:8302–8311. [PubMed] [Google Scholar]
  • 13. Gallo V, Armstrong RC (1995) Developmental and growth factor‐induced regulation of nestin in oligodendrocyte lineage cells. J Neurosci 15:394–406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Geiger KD, Stoldt P, Schlote W, Derouiche A (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 157:1785–1793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Goletz S, Hanisch FG, Karsten U (1997) Novel alphaGalNAc containing glycans on cytokeratins are recognized in vitro by galectins with type II carbohydrate recognition domains. J Cell Sci 110:1585–1596. [DOI] [PubMed] [Google Scholar]
  • 16. Gordower L, Decaestecker C, Kacem Y, Lemmers A, Gusman J, Burchert M, Danguy A, Gabius HJ, Salmon I, Kiss R, Camby I (1999) Galectin and galectin‐3 binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Applied Neurobiol 25:319–330. [DOI] [PubMed] [Google Scholar]
  • 17. Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. Genome Res 6:986–994. [DOI] [PubMed] [Google Scholar]
  • 18. Hirabayashi J, Kasai K (1993) The family of metazoan metal‐independent (‐galactoside‐binding lectins: structure, function and molecular evolution. Glycobiology 3:297–304. [DOI] [PubMed] [Google Scholar]
  • 19. Hoang‐Xuan K, Aguirre‐Cruz L, Mokhtari K, Marie Y, Sanson M (2002) OLIG‐1 and 2 gene expression and oligodendroglial tumours. Neuropathol Appl Neurobiol 28:89–94. [DOI] [PubMed] [Google Scholar]
  • 20. Hughes RC (1997) The galectin family of mammalian carbohydrate‐binding molecules. Biochem Soc Trans 25:1194–1198. [DOI] [PubMed] [Google Scholar]
  • 21. Hughes RC (2001) Galectins as modulator of cell adhesion. Biochemie 83:667–676. [DOI] [PubMed] [Google Scholar]
  • 22. Inohara H, Akahani S, Raz A (1998) Galectin‐3 stimulates cell proliferation. Exp Cell Res 245:294–302. [DOI] [PubMed] [Google Scholar]
  • 23. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225. [DOI] [PubMed] [Google Scholar]
  • 24. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, Graeber S, Herzog V, Pietsch T, Wiestler OD, Probstmeier R (2000) Expression pattern of galectin‐3 in neural tumor cell lines. J Neurosci Res 60:45–57. [DOI] [PubMed] [Google Scholar]
  • 25. Lotan R, Belloni PN, Tressler RJ, Lotan D, Xu XC, Nicolson GL (1994) Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconj J 11:462–468. [DOI] [PubMed] [Google Scholar]
  • 26. Liu FT, Patterson RJ, Wang JL (2002) Intracellular functions of galectins. Biochem Biophys Acta 1572:263–273. [DOI] [PubMed] [Google Scholar]
  • 27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real‐time quantitative PCR and the 2 (‐Delta Delta C(T)) method. Methods 25:402–408. [DOI] [PubMed] [Google Scholar]
  • 28. Lu QR, Park JK, Noll E, Chan JA, Alberta J, Yuk D, Alzamora MG, Louis DN, Stiles CD, Rowitch DH, Black PM (2001) Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 98:10851–10856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, Poirier J, Zalc B, Hoang‐Xuan K (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet 358:298–300. [DOI] [PubMed] [Google Scholar]
  • 30. Menon RP, Strom M, Hughes RC (2000) Interaction of a novel cysteine and histidine‐rich cytoplasmic protein with galectin‐3 in a carbohydrate‐independent manner. FEBS Lett 470:227–231. [DOI] [PubMed] [Google Scholar]
  • 31. Nakagawa Y, Perentes E, Rubinstein LJ (1986) Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers. Acta Neuropathol (Berl) 72:15–22. [DOI] [PubMed] [Google Scholar]
  • 32. Nangia‐Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A (2000) Galectin‐3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899–909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ohnishi A, Sawa H, Tsuda M, Sawamura Y, Itoh T, Iwasaki Y, Nagashima K (2003) Expression of the oligodendroglial lineage‐associated markers Olig1 and Olig2 in different types of human gliomas. J Neuropathol Exp Neurol 62:1052–1059. [DOI] [PubMed] [Google Scholar]
  • 34. Ochieng, J , Leite‐Browning ML, Warfield P (1998) Regulation of cellular adhesion to extracellular matrix proteins by galectin‐3. Biochem Biophys Res Comm 246:788–791. [DOI] [PubMed] [Google Scholar]
  • 35. Park JW, Voss PG, Grabski S, Wang JL, Patterson RJ (2001) Association of galectin‐1 and galectin‐3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res 29:3595–3602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Perentes E, Rubinstein LJ (1986) Immunohistochemical recognition of human neuroepithelial tumors by anti‐Leu 7 (HNK‐1) monoclonal antibody. Acta Neuropathol (Berl) 69:227–233. [DOI] [PubMed] [Google Scholar]
  • 37. Perillo NL, Marcus ME, Baum LG (1998) Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med 76:402–412. [DOI] [PubMed] [Google Scholar]
  • 38. Pohl U, Cairncross JG, Louis DN (1999) Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol 9:639–643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Probstemeier R, Montag D, Schachner M (1995) Galectin‐3, a beta‐galactoside‐binding animal lectin, binds to neural recognition molecules. J Neurochem 64:2465–2472. [DOI] [PubMed] [Google Scholar]
  • 40. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP (2003) Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259–266. [DOI] [PubMed] [Google Scholar]
  • 41. Rabinovich GA (1999) Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death Differ 6:711–721. [DOI] [PubMed] [Google Scholar]
  • 42. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response Trends Immunol 23:313–320. [DOI] [PubMed] [Google Scholar]
  • 43. Riemenschneider MJ, Koy TH, Reifenberger G (2004) Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol (Berl) 107:277–282. [DOI] [PubMed] [Google Scholar]
  • 44. Rutka JT, Apodaca G, Stern R, Rosenblum M (1998) The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 69:155–170. [DOI] [PubMed] [Google Scholar]
  • 45. Sato S, Hughes RC (1992) Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem 267:6983–6990. [PubMed] [Google Scholar]
  • 46. Seve AP, Felin M, Doyennette‐Moyne MA, Sahraoui T, Aubery M, Hubert J (1993) Evidence for a lactose‐mediated association between two nuclear carbohydrate‐binding proteins. Glycobiology 3:23–30. [DOI] [PubMed] [Google Scholar]
  • 47. Strik HM, Deininger MH, Frank B, Schluesener HJ, Meyermann R (2001) Galectin‐3: cellular distribution and correlation with WHO‐grade in human gliomas. J Neurooncol 53:13–20. [DOI] [PubMed] [Google Scholar]
  • 48. Van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B (2003) Second‐line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lo‐mustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599–602. [DOI] [PubMed] [Google Scholar]
  • 49. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin‐3 modulates T‐cell growth and apoptosis. Proc Natl Acad Sci U S A 93:6737–6742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Yang RY, Liu FT (2003) Galectins in cell growth and apoptosis. Cell Mol Life Sci 60:267–276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Yates AJ, Comas T, Scheithauer BW, Burger PC, Pearl DK (1999) Glycolipid markers of astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 58:1250–1262. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES